What insurance policy changes affect code N76.0?

There are 3 tracked policy changes affecting code N76.0, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code N76.0?

Payers that have issued tracked updates for code N76.0 include: Aetna.

How do I get notified when code N76.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code N76.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code N76.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

N76.0 Insurance Policy Changes

ICD-10 N76.0 is officially defined as "Acute vaginitis." code N76.0 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code N76.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 1, 2026Medium impact
Diagnosis of Vaginitis (CPB 0643, reviewed 2026-09-25)
Aetna's vaginitis diagnosis policy (CPB 0643), last reviewed 09/25/2026, considers nucleic acid amplification or DNA probe tests for trichomonas, Candida and Gardnerella medically necessary for members with dysuria or symptoms of vaginitis. It also considers BVBlue sialidase testing, PCR tests for bacterial vaginosis and Candida, and pH and amine testing medically necessary for women with symptoms. Trichomonas screening is considered medically necessary for women with listed risk factors, including HIV-positive women, new or multiple partners, history of sexually transmitted diseases, exchange of sex for payment, injection drug use, or high-prevalence settings. Routine screening of asymptomatic women for Candida and Gardnerella, Pap smears for the diagnosis of Candida vulvovaginitis, the uBiome SmartJane screen and the 27-organism vaginal pathogen panel are experimental, investigational or unproven, and screening asymptomatic pregnant women for bacterial vaginosis is experimental and not covered.
Aetna · Identified Aug 15, 2026Medium impact
Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)
Aetna's clinical policy bulletin for carbon dioxide laser (CPB 0427) lists the uses it considers medically necessary: condyloma, pelvic pain associated with endometriosis, primary penile tumors (clinical stage Tis, Ta, and T1 Grade 1 to 2), refractory plantar warts, removal of actinic keratoses for members who meet CPB 0567 criteria, removal of superficial basal cell carcinomas, and fractional carbon dioxide laser for hypertrophic burn, traumatic, and surgical scars when conventional therapies have failed. Aetna considers carbon dioxide laser experimental, investigational, or unproven for a list of other indications, including hidradenitis suppurativa, male androgenetic alopecia, onychomycosis, port wine stains, stress urinary incontinence, and vaginal atrophy. Aetna considers carbon dioxide laser treatment of other actinic lesions cosmetic.
Aetna · Identified Aug 14, 2026Medium impact
Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)
Aetna considers several vaginitis tests medically necessary for women with symptoms of vaginitis, including nucleic acid amplification or DNA probe assays for trichomonas, Candida and Gardnerella for members with dysuria or symptoms of vaginitis, sialidase activity testing such as the BVBlue test, and pH and amine testing of vaginal fluid. Screening for Trichomonas vaginalis is considered medically necessary for women with risk factors such as HIV-positive status, new or multiple partners, a history of sexually transmitted diseases, exchange of sex for payment, injection drug use, or high-prevalence settings such as STD clinics and correctional facilities. A Pap smear for the diagnosis of Candida vulvo-vaginitis, routine screening for Candida and Gardnerella in asymptomatic women, the uBiome SmartJane screen, and the 27-organism vaginal pathogen panel from Bridge Diagnostics are considered experimental, investigational, or unproven because their effectiveness has not been established.

Watch N76.0

Get one email when a payer policy names N76.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Diagnosis of Vaginitis (CPB 0643, reviewed 2026-09-25)

Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)

Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)

What insurance policy changes affect code N76.0?

Which payers have updated policy for code N76.0?

How do I get notified when code N76.0 policy changes?

Why do payers change policies for code N76.0?